Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists. Our lead candidate, OC459, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with OC459 to rhinovirus infection (common cold); and a Phase 3 clinical trial of patients with moderate persistent eosinophilic asthma in Russia. Our second cadidate, ATX2417, is undergoing a Phase 1 human safety study.
Type
Private
HQ
Milton, GB
Founded
2012
Atopix was founded in 2012 and is headquartered in Milton, GB

Atopix Office Locations

Atopix has an office in Milton
Milton, GB (HQ)
Milton Park Innovation Centre 99 Park Dr

Atopix Data and Metrics

Summary Metrics

Founding Date

2012

Total Funding

$5.1 m

Latest funding size

$5.1 m

Time since last funding

about 2 years

Investors

Atopix's latest funding round in July 2015 was reported to be $5.1 m. In total, Atopix has raised $5.1 m

Atopix Financial Metrics

Atopix's revenue was reported to be £316 k in FY, 2015 which is a 50% decrease from the previous period.
GBP

Net income (FY, 2016)

(3.4 m)

Cash (31-Dec-2016)

431.3 k
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

225.3 k626.7 k316 k

Revenue growth, %

178%(50%)

Pre tax profit

(2.2 m)(2.7 m)(5.2 m)(3.6 m)

Net Income

(2.1 m)(2.5 m)(4.7 m)(3.4 m)
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash

1.9 m2.5 m1.3 m431.3 k

Accounts Receivable

26080

Current Assets

2.4 m3.1 m2.2 m783.2 k

PP&E

64646.3 k3 k

Goodwill

6464

Total Assets

2.4 m3.1 m2.2 m786.2 k

Accounts Payable

102.9 k621.6 k285.1 k181.8 k

Current Liabilities

743.3 k1.4 m2.6 m3.6 m

Total Liabilities

2.2 m3.9 m6.9 m3.6 m

Retained Earnings

(2.1 m)(2.5 m)(4.7 m)(3.4 m)

Total Equity

141 k(812.1 k)(4.7 m)(2.8 m)

Financial Leverage

16.8 x-3.8 x-0.5 x-0.3 x
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(1.8 m)

Cash From Financing Activities

3.7 m

Income Taxes Paid

68.2 k164.1 k525.9 k204.9 k
Y, 2016

Financial Leverage

-0.3 x

Traffic Overview of Atopix

Atopix Company Life and Culture

You may also be interested in